Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 106, Issue 4, Pages 726-733Publisher
WILEY
DOI: 10.1002/cpt.1477
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R24GM115264, U24HG010135, R24GM61374, R24 GM123930]
- CAMH
- Canada Research Chair in Pharmacogenomics
- CIHR [FDN-154294]
- European and Developing Countries Clinical Trial Partnership (EDCTP) [TMA 20016-1508 PRACE TMA2016SF]
- SANBIO/BiofisaII grant
- [R01 AI077505]
- [UM1 AI069439]
- [UM1 AI106701]
- [P30 AI110527]
- [TR 002243]
- [U01 HG007762]
- [R01 GM121707]
- [R01 GM078501]
Ask authors/readers for more resources
The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available